GOSS - Gossamer Bio, Inc.
IEX Last Trade
0.848
-0.013 -1.521%
Share volume: 9,640
Last Updated: Thu 26 Dec 2024 08:28:50 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.86
-0.01
-1.50%
Fundamental analysis
26%
Profitability
25%
Dept financing
11%
Liquidity
50%
Performance
25%
Performance
5 Days
-1.64%
1 Month
20.56%
3 Months
-11.36%
6 Months
-10.22%
1 Year
-2.79%
2 Year
-52.05%
Key data
Stock price
$0.85
DAY RANGE
$0.83 - $0.86
52 WEEK RANGE
$0.53 - $1.60
52 WEEK CHANGE
-$4.40
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Faheem Hasnain
Region: US
Website: gossamerbio.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: gossamerbio.com
Employees: 180
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.
Recent news